Condition primary focal segmental glomerulosclerosis
Treatment rituximab
Phase phase 2
Target CD20
Sponsor Mayo Clinic
Collaborator University Health Network, Toronto
Start date October 2013
End date March 2018
Trial size 20 participants
Trial identifier NCT01573533, 12-005640, U54DK083912


The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional therapies.

Recruiting in the following locations…

United States Minnesota
Other countries Canada

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
rituximab Rituxan®
Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.

Primary Outcomes

Changes in proteinuria (with stable renal function)
time frame: 12 months

Secondary Outcomes

Change in suPAR levels
time frame: 1, 3, 6 and 12 months
Change in activation of podocyte β3 integrin
time frame: 1, 3, 6, 12 months
Duration of complete or partial remission following treatment
time frame: 1, 3, 6, 12 months

Eligibility Criteria

All participants from 6 years up to 80 years old.

Inclusion Criteria: - FSGS involving native kidneys with a diagnostic biopsy performed within the last 3 years - Patients >6 years of age and < 80 years of age - suPAR > 3500 pg ml-1 - Treatment with an ACEI and/or ARB as tolerated for at least 3 months prior to enrollment to with a target a systolic blood pressure ≤ 140 mmHg and a diastolic pressure ≤ 90 mmHg in adults and blood pressure readings less than the 95th percentile for age, gender and height in children in at least 75% of readings - Proteinuria ≥ 3.0 grams as measured by 24-hour urine collection in adults and urine protein:creatinine ratio ≥ 1.0 in the first morning urine in children, despite ACE inhibitor / ARB treatment as tolerated and a minimum of 8 weeks of prednisone therapy at ≥ 1 mg/kg/day, a trial of calcineurin inhibitor for=> 3 months or a contraindication/intolerance to such therapy (diabetes, osteoporosis/osteonecrosis, age >60, BMI ≥35) - Negative serum pregnancy test (for women of child bearing age) - Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of the trial - Able and willing to give written informed consent and comply with study requirements Exclusion Criteria: - Estimated GFR < 40 ml/min per1.73m2. The rationale is that patients with advanced renal failure may progress rapidly towards ESRD. - Collapsing variant of FSGS, as it is rare and has been associated with an aggressive course - Concurrent use of immunosuppressive therapy with the exceptions of prednisone 10 mg/day. Patients who are taking other immunosuppressive therapy, must be off immunosuppressive medications for equal to or > 3 months prior to enrollment into the study with the exception of patients demonstrating significant worsening of proteinuria (of >30% above baseline) during the washout period. These resistant patients can be treated after 1 month of washout due to the high likelihood of progression and/or lack of delayed (previous) immunosuppression effect. - Patients with medical conditions that may cause FSGS (e.g. HIV, lymphoma, heroin use) or have a secondary form of FSGS due to hyperfiltration injury (massive obesity, vesicoureteral reflux, or renal mass reduction) - Type 1 or type 2 diabetes mellitus as diabetic glomerulosclerosis may be contributing to proteinuria in these patients - History of serious recurrent or chronic infection - Presence or suspicion of active infection including TB, HIV, Hepatitis B and HCV with positive tests for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B virus (HBV), Hepatitis C serology, HIV serology or a positive TB skin test, which require further investigation to rule out active disease (ie. chest x-ray) - Known active infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks or oral antibiotics within 2 weeks of the study initiation - Low immunoglobulins (level to be based on age) - Absolute neutrophil count < 1.5 x103/mL - Patients in receipt of a live vaccine within 4 weeks of the study initiation - Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix - Previous Treatment with a B-cell depleting antibody - History of severe allergic reactions to humanized or murine monoclonal antibodies - Treatment with any investigational agent within 4 weeks of the study initiation - History of major psychiatric disorder, drug or alcohol abuse within the previous 6 months - Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory that provides a reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

Additional Information

Official title A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
Principal investigator Michelle Hladunewich, MD, MSc, BSc
Description This is a pilot trial to assess the safety, feasibility and efficacy of Rituximab therapy in 20 adult and pediatric patients with either steroid and/or calcineurin inhibitor resistant FSGS or with a significant intolerance or contraindication to the use of these agents. In addition to clinical criteria, elevated levels of suPAR will define inclusion. Changes in the baseline levels of the potential biomarkers (suPAR, as well as activation of beta-3 integrin) in response to treatment will be compared to clinical measures of efficacy. Participants will have a screening/baseline visit to confirm eligibility within 6 weeks prior to the first of two Rituximab infusions (at Day 1 and Day 15). Participants will then attend follow up visits at 1, 3, 6 and 12 months after Rituximab treatment to assess adverse events and collect safety blood and urine samples.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Mayo Clinic.